Scorpion Therapeutics and Pierre Fabre to Co-Develop and Commercialize STX-721 and STX-241 for Patients with EGFRm NSCLC April 12, 2023
Genenta Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor Indications April 12, 2023
Coeptis Therapeutics Secures Exclusive Rights to Negotiate to Acquire Transformational Cell Therapy Platform to Enable Combinatorial IO Treatment Strategies April 6, 2023
Omega Enters Supply Agreement With Roche To Evaluate OTX-2002 – Atezolizumab combination in HCC April 6, 2023
Bicycle Therapeutics Announces a Strategic Collaboration with Novartis to Discover, Develop and Commercialize Bicycle® Radio-Conjugates April 6, 2023
Jounce Therapeutics Enters Into Agreement to Be Acquired by Concentra Biosciences for $1.85 in Cash per Share Plus Contingent Value Rights March 31, 2023
BioNTech and OncoC4 Announce Strategic Collaboration to Co-Develop and Commercialize Novel Checkpoint Antibody in Multiple Solid Tumor Indications March 31, 2023
Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers March 31, 2023
Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01; DisTinGuish Trial of DKN-01 + tislelizumab & chemo to continue as a clinical collaboration March 31, 2023
Merck Strengthens Oncology Franchise by Securing Exclusive Worldwide Rights to Anti PD-L1 Antibody BAVENCIO® (avelumab) March 31, 2023
Caris Life Sciences and Incyte Enter Into Broad Precision Medicine Partnership to Advance Incyte’s Oncology Pipeline March 15, 2023
Volastra Therapeutics in-licenses Clinical Stage KIF18A Inhibitor And Secures $60 Million in Series A Funding To Further Advance Cancer-Focused Pipeline March 15, 2023
Tachyon Receives Funding from CIRM for a Ph 1 Study of TACH101 in Patients with Advanced Solid Tumors March 15, 2023
Celanese Announces Collaboration with Alessa Therapeutics for the Advancement of Oncology Treatments March 15, 2023
AstraZeneca enters license agreement with KYM Biosciences for CMG901, a Claudin-18.2 antibody drug conjugate February 28, 2023
MEI Pharma and Infinity Pharmaceuticals Announce Definitive Merger Agreement to Advance Three Promising Clinical Oncology Candidates February 28, 2023
Kinnate Biopharma Acquires Ownership Stake from Kinnjiu Biopharma; Initiates Ph 1 Trial for Exarafenib (KIN-2787) in China February 28, 2023
Fusion Pharmaceuticals To Acquire Ph 2 Program For 225Ac-PSMA I&T, A Radiopharmaceutical Targeting metastatic CRPC February 22, 2023
Cullinan Oncology enters into an exclusive license with Harbour BioMed for the development and commercial rights of HBM7008 (CLN-418) in the U.S. February 22, 2023
Gaia Biomedicine & TreeFrog Therapeutics announce collaboration for the expansion of allogeneic NK-like cells against solid tumors February 22, 2023
